Close

Agilent Technologies (A) Reports Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or GEJ Cancer

September 22, 2017 4:28 PM EDT Send to a Friend
Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login